Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

Histologically confirmed adenocarcinoma of the prostate
Primary localized PCa, cN0 and cM0, intermediate or high-risk disease according to NCCN 2023
Signed written informed consent for this study
T2-T3a clinical stage with visible DIL on mpMRI
ECOG 0-1
Desirable prostate volume (not mandatory) \< 80 cc or \> 80 cc if urinary function is preserved and dosimetrically feasible
IPSS ≤ 18 (International Prostate Symptom Score)

Unresolved previous prostatitis, symptomatic urethral stenosis
Bilateral hip prosthesis
T3b-4 clinical stage or N1
M1 (presence of distant metastases)
Previous surgery at the prostate level (Transurethral Resection of the Prostate) within the last 6 months

SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer